Pain, Post Operative Pain
Conditions
Keywords
Pain, postoperative analgesia, Erector spinae plane block, cesarean section
Brief summary
Erector spinae plane (ESP) block is an interfacial plane block with visceral and somatic analgesic activity at paraspinal muscles. This study aims to examine the postoperative analgesic efficacy of ESP block after cesarean section (CS) with Pfannenstiel incision under spinal anesthesia.
Detailed description
The study included 54 patients with mild systemic disease (ASA II patients) who would undergo elective CS under spinal anesthesia. They were randomly divided into an ESP block group (Group E) and a control group (Group C). After the surgery, Group E patients underwent ultrasound-guided bilateral ESP block with 20 ml of 0.25% bupivacaine at the lateral decubitus position, while Group C received no intervention. Patients in both groups received parenteral patient-controlled analgesia. The patients' post-operative 24-hour opioid consumption, regular Visual Analogue Scale (VAS) measurements, and need for rescue analgesics were evaluated. Statistical analysis was performed using SPSS 21 program. Demographic and other data were assessed using independent samples t-test, Mann-Whitney U test, and Chi-square analysis.
Interventions
PROCEDUREControl
No block was performed
PROCEDUREErector spinae plane block
Erector spinae plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
Sponsors
Kahramanmaras Sutcu Imam University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Masking description
Double (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* ASA II patients * 18-45 years who underwent CS with Pfannenstiel incision under spinal anesthesia * agreed to participate in the study
Exclusion criteria
* Patients with infection at the injection site * Coagulopathy Allergy to amide-type local anesthetics * History of peripheral neuropathy * Hepatic and/or renal failure * Refusing the procedure * patients with heart disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 24-hour opioid consumption | up to 24 hour | The amount of tramadol consumed in milligrams in the first 24 hours was determined with a patient-controlled analgesia pump. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analog Scale (Vas) | 0, 30 minutes, 1 hour, 2 hours, 6 hours, 12 hours, 24 hours | pain scores,graded from 0 to 10, 0 no pain, 10 highest pain experienced |
Countries
Turkey (Türkiye)
Outcome results
None listed